Lexaid Founder and CEO Suky Ji Attends the 2026 Fudan Rare Diseases and Precision Medicine Conference

On 18–19 September 2026, Ms. Suky Ji (及淑芳), Founder and CEO of Lexaid (乐小助)—the cross-border medical companion brand of Shanghai Qile Wuyou Technology Co., Ltd. (上海其乐无忧科技有限公司)—attended the 2026 Fudan Rare Diseases and Precision Medicine Conference in Shanghai with Lexaid team members.

The public academic meeting, held in Shanghai, brought together clinicians, researchers, and patient communities around rare disease and precision medicine. Lexaid joined as a cross-border care coordination team, not as a hospital and not as a clinical speaker. Diagnosis and treatment remain with licensed clinicians.

Conference backdrop: Fudan Rare Diseases and Precision Medicine, 18–19 September 2026, Shanghai

During the two days, the team sat in on open sessions—including a briefing titled “Rare diseases by the numbers”—and walked the exhibition wall covering topics such as rare tumors, immunology and rheumatology, multi-system genetic syndromes, and messages between patients and doctors. The visit helped the team hear how families and specialists talk about pathways that are often hard to name, document, and coordinate across borders.

Open session: “Rare diseases by the numbers”

On site: founder and team member at the conference message wall

Lexaid’s work stays on the non-clinical side of a care journey: specialty matching, multilingual communication, and trip coordination for families who may later seek care in China. Attending this conference is a way to keep that coordination closer to how rare-disease pathways are actually discussed—without promising a diagnosis, a drug, or a hospital bed.

Team members taking notes during on-site exchanges

Conference group photo

What Lexaid took away

• Dates and place — 18–19 September 2026, Shanghai. Official schedule: Fudan Big Health Information Research Center.
• Who attended — Founder and CEO Ms. Suky Ji, with Lexaid team members.
• What was observed — public sessions and a patient-and-clinician message wall, not a Lexaid clinical program.
• Boundary — Lexaid does not replace hospitals. Rare-disease decisions stay with the treating team.

Lexaid will keep learning from public academic meetings so international families can ask clearer questions before they travel. Clinical eligibility is always confirmed in writing by the receiving hospital.

Consultation: WhatsApp +86 185 2131 5346 · Email [email protected]
Learn more: www.lexaidmed.com